These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 9493492

  • 1. Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir.
    Tepper VJ, Farley JJ, Rothman MI, Houck DL, Davis KF, Collins-Jones TL, Wachtel RC.
    Pediatrics; 1998 Mar; 101(3):E7. PubMed ID: 9493492
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [A case of HIV encephalopathy with dementia which showed significant improvement after the combination antiretroviral therapy].
    Mizoi Y, Takagi M, Hoshino H, Matsuoka S, Adachi T.
    Rinsho Shinkeigaku; 2000 Feb; 40(2):178-80. PubMed ID: 10835942
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N, Ormrod D, Perry CM, Figgitt DP.
    Paediatr Drugs; 2002 Feb; 4(8):515-53. PubMed ID: 12126455
    [Abstract] [Full Text] [Related]

  • 8. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.
    Mueller BU, Nelson RP, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Katz TT, Higham C, Aker D, Edgerly M, Jarosinski P, Serchuck L, Whitcup SM, Pizzuti D, Pizzo PA.
    Pediatrics; 1998 Mar; 101(3 Pt 1):335-43. PubMed ID: 9480994
    [Abstract] [Full Text] [Related]

  • 9. Protease inhibitor therapy in children with perinatally acquired HIV infection.
    Rutstein RM, Feingold A, Meislich D, Word B, Rudy B.
    AIDS; 1997 Oct; 11(12):F107-11. PubMed ID: 9342062
    [Abstract] [Full Text] [Related]

  • 10. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E, MOBIDIP study group.
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [Abstract] [Full Text] [Related]

  • 11. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [Abstract] [Full Text] [Related]

  • 12. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S, GESIDA 7011 Study Group.
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [Abstract] [Full Text] [Related]

  • 13. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
    Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H.
    J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
    [Abstract] [Full Text] [Related]

  • 14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 15. [A case of acquired encephalopathy in a child. A cause that we thought had disappeared].
    Monpoux F, Pitelet G, Richelme C, Boutté P.
    Arch Pediatr; 2008 Dec 11; 15(12):1769-71. PubMed ID: 18993038
    [Abstract] [Full Text] [Related]

  • 16. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 11; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 17. HIV positive patient with HSV-2 encephalitis: case report.
    Pagliano P, Ascione T, Carleo MA, Boccia G, De Caro F, Tortora F.
    Infez Med; 2016 Sep 01; 24(3):245-9. PubMed ID: 27668908
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S, Lathouwers E, Van de Casteele T, Kakuda TN, Opsomer M.
    Pediatr Infect Dis J; 2014 Sep 01; 33(9):940-5. PubMed ID: 25361024
    [Abstract] [Full Text] [Related]

  • 19. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ, GARDEL Study Group.
    Lancet Infect Dis; 2014 Jul 01; 14(7):572-80. PubMed ID: 24783988
    [Abstract] [Full Text] [Related]

  • 20. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA, SECOND-LINE Study Group.
    Lancet HIV; 2017 Jan 01; 4(1):e13-e20. PubMed ID: 27815068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.